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Abstract
Purpose: To ﬁnd potentially diagnostic texture analysis (TA) features and to
evaluate the diagnostic accuracy of two-dimensional (2D) magnetic resonance
(MR) TA for diﬀerentiation between hepatocellular carcinoma (HCC) and benign
hepatocellular tumors in the non-cirrhotic liver in an exploratory MR-study.
Materials and methods: 108 non-cirrhotic patients (62 female; 41.5  18.3 years)
undergoing preoperative contrast-enhanced MRI were retrospectively included in
this multi-center-study. TA including gray-level histogram, co-occurrence and
run-length matrix features (total 19 features) was performed by two independent
readers. Native fat-saturated-T1w and T2w as well as arterial and portal-venous
post contrast-enhanced 2D-image-slices were assessed. Conventional reading was
performed by two separate independent readers. Diﬀerences in TA features
between HCC and benign lesions were investigated using independent sample
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t-tests. Logistic regression analysis was performed to obtain the optimal number/
combination of TA-features and diagnostic accuracy of TA analysis. Sensitivity
and speciﬁcity of the better performing radiologist were compared to TA analysis.
Results: The highest number of signiﬁcantly diﬀering TA-features (n ¼ 5) was
found using the arterial-phase images including one gray-level histogram
(skewness, p ¼ 0.018) and four run-length matrix features (all, p < 0.02). The
optimal binary logistic regression model for TA-features of the arterial-phase
images contained 13 parameters with an accuracy of 84.5% (sensitivity 84.1%,
speciﬁcity 84.9%) and area-under-the-curve of 0.92 (95%-conﬁdence-interval
0.85e0.98) for diagnosis of HCC. Conventional reading yielded a signiﬁcantly
lower sensitivity (63.6%, p ¼ 0.027) and no signiﬁcant diﬀerence in speciﬁcity
(94.6%, p ¼ 0.289) at best.
Conclusion: 2D-TA of MR images is a feasible objective method that may help to
distinguish HCC from benign hepatocellular tumors in the non-cirrhotic liver. Most
promising results were found in TA features in the arterial phase images.
Keywords: Health profession, Medical imaging, Medicine
1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer, the most com-
mon primary malignant liver tumor and in men the second leading cause of death
due to cancer worldwide [1]. While HCC most frequently arises in a cirrhotic liver
[2], depending on the population, about 7.2e42.6% of HCCs also arise in non-
cirrhotic livers [3, 4, 5, 6]. Due to its high overall diagnostic accuracy for focal liver
lesions, contrast-enhanced magnetic resonance (MR) imaging is currently the mo-
dality of choice for distinction of HCC and benign liver lesions in cirrhotic and
non-cirrhotic livers [7, 8]. However, diﬀerentiation of HCC from focal nodular hy-
perplasia (FNH) and hepatic adenoma (HA) with atypical appearance is not always
possible in the non-cirrhotic liver using state-of the art non-invasive or invasive tech-
niques [9, 10].
Although most HCCs can be detected by MRI there is limited diagnostic accuracy
for atypical lesions in the non-cirrhotic liver, even with hepatocyte-speciﬁc contrast
media as all hepatocellular tumors might lack or show hepatocyte-speciﬁc contrast
media uptake [11, 12].
Biopsy is performed in those cases to obtain histopathological diagnosis [13]
although it is known that a liver biopsy is limited by a sampling error and high in-
terreader variability, possibly leading to a false diagnosis due to tumor heterogeneity
[14, 15]. Moreover, liver biopsy has the potential risk of tumor cell dissemination
and intervention related complications like bleeding or infection. However, reliable
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biomarkers are needed to obtain an early diagnosis as the outcome for patients de-
pends on the grade of HCC dediﬀerentiation [16, 17].
Texture analysis (TA) is an objective region-of-interest (ROI) based image process-
ing method, which allows to evaluate gray-level image features without the limita-
tions of subjective judgment of a reader [18, 19]. Using TA, the structure of the
analyzed image is assessed on several levels, e.g. its distribution of gray-levels in
general or in neighboring voxels, and objective measures are derived. In recent years
various studies have implemented TA of two-dimensional (2D) MR-images in
diﬀerent parts of the body such as brain [20], prostate [21], breast [22] and liver
[23]. In these studies TA proofed to be a promising technique to distinguish or clas-
sify benign and malignant lesions [20, 21, 22, 23].
The purpose of our study was to ﬁnd potentially diagnostic TA features and to eval-
uate the diagnostic accuracy of 2D-MR-TA for diﬀerentiation between HCC and
benign hepatocellular tumors in the non-cirrhotic liver in an MR-study.
2. Materials and methods
This study included data from an internationally registered multi-center study (Clin-
icalTrials.gov: NCT01234701). Institutional review board approval was obtained at
the Ethics committee of the Canton Zurich and a waiver of written informed consent
was obtained in each site. Data of this study population or parts of it were previously
reported in diﬀerent contexts [24, 25].
2.1. Study population
A total of 108 non-cirrhotic patients (group: median age 45, range 18e85; females (n
¼ 62): 37.5, 18e85; males (n ¼ 46): 55.5, range 24e81) were retrospectively
included in this multi-center study of ﬁve large international cancer care centers be-
tween January 2006 and June 2010. All patients underwent liver resection due to
HCC, HA or FNH. Inclusion criteria were 1) age over 18 years, 2) no contraindica-
tions for MR-scanning, 3) contrast-enhanced MRI within two months prior to sur-
gery 4) partial liver resection, 5) histopathological diagnosis of HCC, HA or FNH
based on the total resected specimen, and 6) histopathological evidence of non-
cirrhotic liver-structure surrounding the lesion. Final diagnosis of the tumor was
based on histopathology of the largest liver lesion of each patient.
2.2. Histopathological analysis
Macroscopic analysis, tissue sampling of the lesion and the surrounding liver paren-
chyma as well as an immunohistochemistry analysis was performed in all specimens
by the local pathologist at each of the ﬁve centers according to local protocols. In
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patients with more than one liver lesion a radiologist, who was not involved in the
image analysis, marked the resected lesion by slice position and location according
to the hepatic segment numbering system of Couinaud.
2.3. Magnetic resonance imaging
Image acquisition was performed on 1.5T MRI-scanners (1xGenesis Signa, 1xSigna
Horizon, GE Healthcare, Waukesha, WI; 1xSonata, 2xAvanto, Siemens Healthcare,
Erlangen, Germany). For MR-imaging local optimized clinical protocols were used.
All MRI-protocols comprised of a spin-echo T2-weighted (T2w) sequence and a
native fat-saturated gradient-echo T1-weighted (fs-T1w) sequence. Contrast-
enhanced fat-saturated gradient-echo T1-weighted sequences according to local
optimized MRI-liver-protocols were obtained using an extracellular-ﬂuid agent, a
hepatobiliary-speciﬁc agent or extracellular-ﬂuid agent in combination with a
reticuloendothelial-speciﬁc agent. Gadoterate meglumine (Dotarem, Guerbet
AG, Zurich, Switzerland), gadoteridol (ProHance, Bracco, Milan, Italy) and gado-
butrol (Gadovist, Bayer Schering Pharma AG, Leverkusen, Germany) were used as
extracellular-ﬂuid agents, gadoxetic acid (Primovist, Bayer AG, Leverkusen, Ger-
many) and gadobenate dimeglumine (MultiHance, Bracco, Milan, Italy) as
hepatobiliary-speciﬁc agent and ferucarbotran (Resovist, Bayer Schering Pharma
AG, Leverkusen, Germany) at doses as speciﬁed by the manufacturer. All protocols
included acquisition of an arterial phase (10 seconds after contrast application) and a
portal-venous phase (60 seconds after contrast application). In all patients, who
received the hepatobiliary-speciﬁc agent a hepatospeciﬁc phase was acquired
(10e30 minutes after contrast application). Relevant acquisition parameters can
be found in Table 1.
2.4. Image analysis
2D-TA was implemented in Matlab (MathWorks, Natick, MA) based on work of
Vallieres et al. [26] and Wei [27]. In short, gray-levels in the placed ROI were ﬁrst
normalized. Then the ﬁrst-level TA-features based on the histogram of all gray-
levels in the ROI were computed (variance, skewness, kurtosis, entropy). Subse-
quently, the gray-level co-occurrence matrix (GLCM) was constructed based on
the gray-level distribution within the ROI as introduced by Haralick et al [28].
Brieﬂy, this matrix contains the distribution of all possible pairs of gray-levels in
neighboring pixels of a given image. Using the GLCM the second-level TA-features
contrast, correlation, energy and homogeneity were derived. Finally, the gray-level
run-length matrix (GLRLM) was constructed. This matrix basically depicts the dis-
tribution of the number of neighboring pixels with the same gray-levels on a straight
line in a given image. From the GLRLM the second-level TA-features short-run
emphasis (SRE), long-run emphasis (LRE), gray-level nonuniformity (GLN),
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Table 1. Important MR sequence parameters. T1-weighted native and contrast-enhanced as well as T2-weighted images were used for texture analysis
and for conventional reading. Additionally, in- and opposed-phase gradient-echo sequences were analyzed for conventional reading. In institution 1 after
application of extracellular contrast medium a reticuloendothelial-speciﬁc contrast agent ferucarbotran (0.5 mmol Fe/ml) was additionally applied. None
of the sequences with reticuloendothelial-speciﬁc contrast agent were used for texture analysis or conventional reading.
Institution Sequence Acquisition parameter Contrast agent
Orientation Matrix ST [mm] TR [ms] TE [ms] FA [] Extracellular hepatocytespediﬁc
1 T2 FS RT Axial 256  196 5 9474 105 90 Gadoterate meglumine
(0.5 mmol Gd/ml)
Gadoxetic acid
(0.25 mmol Gd/ml)
T1 LAVA native Axial 256  224 4 3 1.4 15
T1 LAVA dynamic Axial 256  224 4 3 1.4 15
T1 in/opp Axial 224  192 5 135 2.2/4.7 60
2 T2 HASTE fat sat Axial 256  218 4 1100 87 150 Gadoterate meglumine
(0.5 mmol Gd/ml)
T1 VIBE 3D native Axial 512  176 3 3.5 1.6 12
T1 VIBE 3D dynamic Axial 512  176 3 3.5 1.6 12
T1 FLASH in/out Axial 256  158 7 120 2.4/4.8 70
3 T2 FRFSE Axial 256  160 8 2500 91 90 Gadoteridol
(0.5 mmol Gd/ml)
Gadobenate dimeglumine
(0.5 mmol Gd/ml)
T1 native Axial 256  192 6 4.3 1.9 15
T1 FS dynamic Axial 256  192 6 4.3 1.9 15
T1 in/opp Axial 256  160 10 180 2.2/4.7 85
(continued on next page)
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Table 1. (Continued )
Institution Sequence Acquisition parameter Contrast agent
Orientation Matrix ST [mm] TR [ms] TE [ms] FA [] Extracellular hepatocytespediﬁc
4 T2 HASTE Axial 256  205 5 1000 62 150 Gadoteridol
(0.5 mmol Gd/ml)
Gadobenate dimeglumine
(0.5 mmol Gd/ml)
T1 VIBE 3D native Axial 320  166 3 5.2 2.4 10
T1 VIBE 3D dynamic Axial 320  166 3 5.2 2.4 10
T1 FLASH in/opp Axial 256  208 8 94 2.2/4.9 70
5 T2 HASTE Axial 320  218 5 1200 66 180 Gadobutrol
(1 mmol Gd/ml)
Gadoxetic acid
(0.25 mmol Gd/ml)
T1 VIBE 3D native Axial 320  189 3.5 4.8 2.1 13
T1 VIBE 3D dynamic Axial 320  189 3.5 4.8 2.1 13
Abbreviations: slice thickness (ST); repetition time (TR); echo time (TE); ﬂip angle (FA); T1-weighted imaging (T1); T2-weighted imaging (T2); fat saturated (FS); respiratory trigger (RT); liver
acquisition with volume acceleration (LAVA); half Fourier acquisition single shot turbo spin echo (HASTE); volume interpolated breath hold examination (VIBE); fast relaxation fast spin echo
(FRFSE); fast low angle shot (FLASH); in-phase and opposed-phase imaging (in/opp).
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run-length nonuniformity (RLN), run percentage (RP), low gray-level run emphasis
(LGRE), high gray-level run emphasis (HGRE), short-run low gray-level emphasis
(SRLGE), short-run high gray-level emphasis (SRHGE), long-run low gray-level
emphasis (LRLGE), and long-run high gray-level emphasis (LRHGE) were ob-
tained. Principles of generating GLCM and GLRLM are summarized in Fig. 1.
To minimize the possible impact of the needed choice of a direction for the construc-
tion of GLCM and GLRLM second-level TA-features were calculated for all four
possible directions and mean values were used for further investigations. Images
with severe artefacts resulting in non-deﬁnable or only partial deﬁnable, not allowing
classifying the lesion, were excluded.
For the actual 2D-TA two readers (TA Readers 1 and 2: DS and HM, 2 and 5 years
experience in abdominal imaging), blinded to the pathologic diagnostic results as
well as the results of each other, independently selected the slice containing the
largest diameter of the largest liver lesion in the acquired T2w and native fs-T1w
images, the arterial phase, portal-venous phase and if available hepatobiliary phase
Fig. 1. Schematic overview of the texture analysis process. First, a ROI has to be drawn covering the
assessed lesion (a) (green overlay in the upper left). For demonstration purposes projected in the middle
of the image with arbitrarily selected and arranged ﬁctive pixels with diﬀerent gray-levels numbered from
one to four as an example (b). From the matrix of values within the ROI a GLCM* (c), a GLRLM* (d)
and a histogram (e) is computed. For the GLCM each pixel of the image is scanned and used as a “refer-
ence pixel” once. This pixel is then compared with the pixel in a given distance and direction (0, 45,
90 or 135), the “neighbour pixel”. When a reference value and a neighbour value pair are found, the
GLCM is increased by 1 in the respective column and row (in the example above two pairs of 1:2 are
found and a 2 is added in the matrix accordingly). GLRLM quantiﬁes runs of the same gray-level in a
given direction (0, 45, 90 or 135). Diﬀerent to the GLCM the GLRLM has run lengths plotted on the
y-axis. The example above shows a run of three 2s and a 1 is added in the matrix accordingly. *for the
shown example, a distance of 1 and a direction of 0 was used.
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images. Subsequently a ROI was deﬁned in this slice including the whole lesion (cp.
Fig. 2) and the 19 TA-features described above were calculated.
Additionally, the same sequences, as well as, if available, supplementary in- and
opposed-phase gradient-echo sequences were read by two board-certiﬁed radiologists
blinded to all clinical ﬁndings (MR Readers 1 and 2: not authors of the manuscript, 11
and 13 years experience in abdominal imaging). Each lesion was diagnosed as HCC,
HA, FNH or cyst, based on the readers personal experience, by applying commonly
used MRI-criteria such as contrast enhancement in the arterial phase, contrast media
wash-out in the portal venous phase, hyper-enhancement of the capsule in the portal
venous phase and vessel invasion. Based on this diagnose the results of both MR
readers were classiﬁed as either benign or malignant for further analysis.
2.5. Statistical analysis
Interreader agreement for all TA-features and MR-sequences was assessed using the
intra-class correlation coeﬃcient (ICC), interreader agreement for conventional
reading was measured using Cohen’s kappa. An ICC of 0.75e1.00 indicated excel-
lent, 0.60e0.74 good, 0.40e0.59 fair and <0.4 poor agreement. A kappa of
0.81e1.00 indicated very good, 0.61e0.80 good, 0.41e0.60 moderate, 0.21e0.40
fair and <0.20 poor agreement. Independent Student-t-tests were used to detect sig-
niﬁcant diﬀerences in TA-features between HCCs and benign liver lesions. Further-
more, a logistic regression analysis was performed to evaluate the optimal number
and combination of TA-features along with the achieved diagnostic accuracy for
each MRI-sequence separately. The receiver-operating-characteristic (ROC) curves
for the ﬁnal models were constructed and the respective area-under-the-curve (AUC)
as well as their 95% conﬁdence intervals computed. Sensitivity and speciﬁcity
Fig. 2. Typical placement of ROIs in axial MR-images, containing the largest diameter of the lesion.
Upper row: native fs-T1w image (a), arterial phase (b), portal-venous phase (c) and T2w image (d).
Lower row: manual drawn ROIs covering the whole lesion in blue, native fs-T1w image (e), arterial
phase (f), portal-venous phase (g) and T2w image (h).
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between best performing binary logistic regression model and better performing
radiologist were compared using McNemar’s test. All statistical analyses were per-
formed using SPSS (IBM SPSS Statistics 22; SPSS Inc., Chicago IL). p< 0.05
was considered statistically signiﬁcant.
3. Results
53 patients underwent MRI-examination with extracellular-ﬂuid contrast agent, 43
patients with hepatobiliary-speciﬁc contrast agent and 12 patients with
extracellular-ﬂuid contrast agent in combination with a reticuloendothelial-speciﬁc
contrast agent at a dose speciﬁed by the manufacturer (Table 1). MRI phases with
reticuloendothelial-speciﬁc contrast agent were not included into TA. 43 patients
had more than one lesion, the presence of satellite lesion was evaluated in conven-
tional reading but were not used for TA.
We received histopathological results from the local pathologist of each center with
the diagnosis of HCC, HA or FNH as well as the conﬁrmation of non-cirrhotic sur-
rounding liver parenchyma. No results of lesion sub-classiﬁcations were gathered.
For TA-features ICC between the readers showed good to excellent agreement for
the arterial (0.68e0.99, median 0.96), portal-venous (0.73e0.99, median 0.92),
and hepatobiliary phase images (0.64e0.98, median 0.92). Fair to excellent agree-
ment was observed for the native fs-T1w images (0.51e0.99, median 0.95) as
well as for the T2w images (0.51e0.99, median 0.92). Therefore, the data of TA
Reader 1 only was used for further analysis.
ROI deﬁnition was not possible in 10 out of 108 patients for the arterial phase im-
ages, 8 in the portal-venous phase images, 9 in the hepatobiliary phase images, as
well as 9 in the native fs-T1w and 7 in the T2w images due to a missing MR
sequence, non-deﬁnable lesion, missing fat saturation or insuﬃcient image quality.
A ﬂow-chart depicting the formation of the ﬁnal study cohort can be found in Fig. 3.
55 patients had histopathological conﬁrmed HCC, 24 HA and 29 FNH. In the arterial
phase 53 of 97 (55%) patients had an identiﬁable liver lesion histopathologically
conﬁrmed as HCC, 53 of 99 (54%) in the portal-venous and 54 of 98 (55%) in the
hepatobiliary phase as well as 52 of 98 (53%) in the native fs-T1w and 53 of 100
(53%) in the T2w images.
Multiple TA-features showed statistically signiﬁcant diﬀerences between the HCC
group and the benign liver lesion group for almost all used MRI sequences. The ma-
jority of TA-features with statistically signiﬁcant diﬀerences between HCCs and
benign lesions were found when arterial phase images were assessed (n ¼ 5). These
TA-features included skewness (p ¼ 0.018) as a gray-level histogram feature and
LGRE (p ¼ 0.001), SRLGE (p ¼ 0.001), SRHGE (p ¼ 0.021) and LRLGE (p ¼
9 https://doi.org/10.1016/j.heliyon.2018.e00987
2405-8440/ 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article Nowe00987
0.001) as run-length matrix features. Two TA-features with statistically signiﬁcant
diﬀerences between the groups were found in the portal-venous phase images
(LGRE p ¼ 0.028; SRLGE p ¼ 0.038) and one in the native fs-T1w images (skew-
ness p ¼ 0.009). No statistically signiﬁcant diﬀerences could be found when TA-
features parameters in the T2w-images and in the hepatobiliary-phase images
were assessed. Of note, although we found signiﬁcant diﬀerences of some image fea-
tures, there were also areas of overlap of these imaging features in HCCs and benign
liver lesions. Box-plots of TA-features with signiﬁcant diﬀerences between benign
lesions and HCC for each patient are illustrated in Fig. 4.
Fig. 3. Flow chart depicting the formation of the ﬁnal study cohort. Abbreviations: T1-weighted arterial
phase (art); T1-weighted portal-venous phase (pv); T1-weighted hepatobiliary phase (hb); T1-weighted
native sequence (nat); T2-weighted sequence (T2w).
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The ﬁnal model obtained by binary logistic regression analysis comprised of 13 TA-
features for the arterial phase images, including skewness, contrast, correlation, en-
ergy, homogeneity, entropy, LRE, GLN, RLN, LGRE, HGRE, SRLGE and LRLGE.
82 of 97 (84.5%) lesions were correctly diagnosed as HCC or benign lesions with
this model. In the portal-venous phase images the resulting ﬁnal model correctly
diagnosed 66 of 99 lesions (66.7%), including six TA-features (kurtosis, contrast,
correlation, LRE, RP, LGRE), 77 of 98 lesions (78.6%) in the hepatobiliary phase
images, including eight TA-features (homogeneity, SRE, LRE, GLN, RLN, RP,
HGRE, LRHGE), 67 of 98 lesions (68.4%) in the native fs-T1w images, including
two TA-features (contrast, SRLGE), and 66 of 99 lesions (66.7%) including ﬁve
TA-features (contrast, correlation, homogeneity, HGRE, SRHGE) in the T2w im-
ages. These results, including diagnostic accuracy, sensitivity and speciﬁcity are
summarized in Table 2. The respective contingency tables are provided in Table 3.
ROC analysis yielded an AUC of 0.92 (95% conﬁdence interval 0.85e0.98) for the
arterial phase, 0.73 (95% conﬁdence interval 0.63e0.83) for the portal-venous
phase, 0.81 (95% conﬁdence interval 0.72e0.90) for the hepatobiliary phase, 0.77
(95% conﬁdence interval 0.68e0.86) for the native fs-T1w images and 0.68 (95%
conﬁdence interval 0.58e0.79) for the T2w images. All resulting ROC-curves are
presented in Fig. 5.
Interreader agreement for conventional reading was fair with a kappa value of 0.33.
84 of 107 (78.8%) lesions were correctly diagnosed by MR Reader 1 and 67 of 107
lesions (62.6%) by MR Reader 2. These results, including diagnostic accuracy,
sensitivity and speciﬁcity are summarized in Table 2.
Sensitivity of the optimal binary logistic regression model derived from arterial phase
images for the diagnosis of HCC versus benign liver lesions was statistically
Fig. 4. Box-plots for TA-features with signiﬁcant diﬀerences between benign liver lesions and HCC.
Upper line: T1-weighted arterial phase; Skewness (a), LGRE (b), SRLGE (c), SRHGE (d), LRLGE
(e). Middle line: T1-weighted portal-venous phase; LGRE (f), SRLGE (g). Lower line: T1-weighted
native sequence; Skewness (h). Abbreviations: LGRE (low gray-level run emphasis); SRLGE (short-
run low gray-level emphasis); SRHGE (short-run high gray-level emphasis); LRLGE (long-run low
gray-level emphasis).
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Table 2. Summarized diagnostic accuracy, sensitivity and speciﬁcity for the diagnosis of HCC versus benign liver lesions with the associated TA-
features of the ﬁnal model obtained by binary logistic regression analysis. Fractions of absolute numbers are shown in parenthesis. *Histogram TA-
features, yGLCM-TA-features, zGLRLM-TA-features.
fs-T1w native Arterial Portal-venous Hepatobilary T2w MR Reader 1 MR Reader 2
Diagnostic accuracy [%] 68.4 (67/98) 84.5 (82/97) 66.7 (66/99) 78.6 (77/98) 66.7 (66/99) 78.8 (84/107) 62.6 (67/107)
Sensitivity [%] 78.8 (41/52)
95% CI 67.7e89.9
84.9 (45/53)
95% CI 75.3e94.5
83.0 (44/53)
95% CI 72.9e93.1
81.5 (44/54)
95% CI 71.1e91.8
79.2 (42/53)
95% CI 68.3e90.2
63.6 (35/55) 40.0 (22/55)
Speciﬁcity [%] 56.5 (26/46)
95% CI 42.2e70.8
84.1 (37/44)
95% CI 73.3e94.9
47.8 (22/46)
95% CI 33.4e62.3
75.0 (33/44)
95% CI 62.2e90.6
52.2 (24/46)
95% CI 37.7e66.6
94.2 (49/52) 86.5 (45/52)
Number of TA-features 2 13 6 8 5
TA-features contrasty skewness* kurtosis* homogeneityy contrasty
SRLGEz entropyy contrasty SREz correlationy
contrast y correlationy LREz homogeneityy
correlationy LREz GLNz HGREz
energy y RPz RLNz SRHGEz
homogeneityy LGREz RPz
LREz HGREz
GLNz LRHGEz
RLNz
LGREz
HGREz
SRLGEz
LRLGEz
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signiﬁcant higher than sensitivity of MR Reader 1 (p ¼ 0.027), while no statistically
signiﬁcant diﬀerence could be observed between the respective speciﬁcities (p ¼
0.289).
An example of misclassiﬁcation of both MR readers and correct classiﬁcation by TA
is shown in Fig. 6.
4. Discussion
In the present study we could show, that 2D-TA is a feasible method to distinguish
malignant from benign hepatocellular tumors in the non-cirrhotic liver. Most prom-
ising results were obtained when assessing arterial phase images, where the most sta-
tistically diﬀering TA-features (including gray-level histogram as well as run-length
matrix features) between HCCs and benign hepatocellular tumors as well as the
Table 3. Contingency table for all assessed MRI sequences comparing results of
TA using the ﬁnal regression model with the histopathological conﬁrmed
diagnoses.
MRI sequence Histopathology
HCC benign liver lesion
fs-T1w native TA logistic regression model HCC 41 20
benign liver lesion 11 26
arterial TA logistic regression model HCC 45 7
benign liver lesion 8 37
portal-venous TA logistic regression model HCC 44 24
benign liver lesion 9 22
hepatobiliary TA logistic regression model HCC 44 11
benign liver lesion 10 33
T2w TA logistic regression model HCC 42 22
benign liver lesion 11 24
Fig. 5. ROC-curves of the ﬁnal model obtained by binary logistic regression analysis for the diﬀerent
assessed MR images. Resulting AUC was 0.92 for the arterial phase, 0.73 for the portal-venous phase,
0.81 for the hepatobiliary phase images, 0.77 for the native fs-T1w, and 0.68 for the T2w images.
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highest sensitivity, speciﬁcity and diagnostic accuracy for the correct classiﬁcation
of HCC were observed. In comparison to conventional reading the derived binary
logistic regression model for TA-features of arterial phase images showed a statisti-
cally signiﬁcant increased sensitivity while no statistical diﬀerences in speciﬁcity
could be found.
Current American Association for the Study of Liver Disease (AASLD) guidelines
(which were partly adopted by the European Association for the Study of the Liver
(EASL)) state that HCC can be diagnosed by dynamic contrast-media (CM)
enhanced MRI showing arterial CM uptake followed by washout of CM in the
venous delayed phases for tumors larger than 1 cm in cirrhotic patients or patients
with chronic hepatitis B [29, 30]. These features as well as the presence or absence
of a pseudocapsule also play a major role in the liver imaging reporting and data sys-
tem (LIRADS), which was introduced by the American College of Radiology (ACR)
to standardize reporting and diagnosis of HCC in patients at high risk [31]. However,
all these features remain qualitative and therefore are prone to subjective misinter-
pretation. TA on the other hand provides objective quantitative measures and there-
fore e besides the deﬁnition of a ROI e lacks this subjective component. This
behavior was conﬁrmed in our study showing a substantially higher interreader
agreement for TA than for conventional reading.
MRI speciﬁc imaging features of HCC should only be applied in patients with
cirrhosis or patients with chronic hepatitis B who may not have developed cirrhosis
yet [29]. Although cirrhosis is the strongest predisposing factor for HCC the annual
incidence of HCC in the non-cirrhotic liver is as high as 0.4% [32]. Still there are no
Fig. 6. Axial MR-images of a hepatocellular carcinoma in liver segment VI in a 64-year-old female pa-
tient. Upper row from left to right: native fs-T1w image (a), arterial phase (b), portal-venous phase (c)
and hepatobiliary phase (d). Lower row from left to right: T2w image (e), fs-T2w image (f), in phase (g)
and opposed phase (h). This lesion presents hypointense in native T1w and hyperintense in T2w and fs-
T2w images. Furthermore, a T2w hyperintense central scar with increased contrast-enhancement in the
hepatobiliary phase as well as slightly increased contrast-enhancing in the arterial phase compared with
the surrounding liver parenchyma is seen. There was no signiﬁcant change in signal intensity from the in-
to the opposed-phase. Both MR readers misclassiﬁed this hepatocellular carcinoma as a focal nodular
hyperplasia and hepatic adenoma, respectively, whereas texture analysis classiﬁed it correctly.
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general guidelines for diagnosis of HCC in the non-cirrhotic patient. Therefore, LIR-
ADS and EASL imaging criteria are commonly used for the classiﬁcation of lesions
in a non-cirrhotic liver as there are no systematic alternatives at the moment. Further-
more, Lin et.al [9] showed a lower sensitivity (78.9 % for CT and 65.0% for MRI) for
the diagnosis of HCC in non-cirrhotic patients when compared to cirrhotic patients
(85.3% for CT and 80.0% for MRI) and to our knowledge no study has assessed
speciﬁcity in the non-cirrhotic patient yet.
While several TA-features showed statistically signiﬁcant diﬀerences between
benign liver lesions and HCC a signiﬁcant overlap exists. This overlap limits the
use of single TA-features for the correct classiﬁcation of liver lesions even if the
most appropriate MR sequence was used. Models using a combination of TA-
features may provide a better approach to discriminate benign from malignant le-
sions. Indeed, using the optimal logistic regression model of TA-features we found
a sensitivity of 84.9% and a speciﬁcity of 84.1% for the correct distinction of HCC
from resected (and therefore most likely atypical) benign liver lesions, almost reach-
ing the performance of MRI in patients with chronic liver disease (mainly cirrhosis,
sensitivity 88%, speciﬁcity 94% [8]) and outperforming the diagnostic accuracy of
conventional reading in the present study.
During hepatocarcinogenesis from a dysplastic nodule over early HCC and well-
diﬀerentiated HCC to poor-diﬀerentiated HCC a typical shift from a portal vein
dominated vascular supply to an arterial dominated vascular supply of the lesion
is usually observed. When evaluating the assessed image sequences, we found the
most promising results for the arterial phase images to distinguish HCC from benign
liver lesions, while the accuracy for the portal-venous and hepatobiliary phase was
worse. The above described transformation of the vascular supply during the step-
wise development of HCC as well as the formation of leaky vessels in HCCs might
be a possible explanation for this observation. The relative lack of diﬀerences of TA-
features between HCC and HA as well as atypical FNH in the portal-venous and hep-
atobiliary phase images might be explained with the known similar behavior of HCC
and HA in those phases due to a similar drainage pattern and commonly missing
functional hepatocytes in these lesions. The poor performance for TA of the T2w
images, however, might be explained with the heterogeneous data-set as both fat-
saturated and non-fat-saturated T2w images were part of the data.
The following study limitations must be taken into account. First, MR-studies were
acquired at diﬀerent MR-scanners using locally optimized protocols and diﬀerent
contrast agents. This might have added to the observed variability and decreased
measured sensitivity, speciﬁcity as well as diagnostic accuracy and might has also
aﬀected the diagnostic performance of TA. However, this setup reﬂects the current
status of liver imaging at diﬀerent centers and even in this setting signiﬁcant diﬀer-
ences could be observed. The potential impact of sequence parameters and image
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quality on TA-features was not part of this study and has to be evaluated in further
studies. Second, additional sequences such as diﬀusion weighted imaging sequences
might have improved the results of conventional reading and TA. Third, the obtained
results are only valid for the used acquisition parameters and cannot be generalized
for diﬀerent MR-image acquisitions as these might have an inﬂuence on the derived
TA-features. Fourth, a selection bias of the included lesions might be present as only
resected liver lesions were included. Furthermore, due to the exploratory nature of
the present study and the main goal to identify potentially diagnostic TA features,
the derived binary logistic regression models were not rigorously corrected for mul-
tiple comparisons. Consecutively these results need to be validated in further future
studies in a prospective manner.
In conclusion, we could show that 2D-texture-analysis of MR images is a feasible
objectivemethod that may help to distinguishmalignant from benign hepatocellular tu-
mors. The most promising results were found in TA features in the arterial phase
images.
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